Dr. Mohammad Dahrouj, MD., PHD.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 954
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Medical University of South Carolina College of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MA license 278738 · NH license 22949
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Massachusetts Eye and Ear Infirmary - Boston, MA
Medical groups
- Massachusetts Eye and Ear Associates, Inc (433 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 954
- Services billed
- 6,057
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Imaging of retina | 2,165 | 838 |
| Injection of drug into eye | 974 | 235 |
| Established patient complete exam of visual system | 447 | 404 |
| Established patient office or other outpatient visit, 30-39 minutes | 381 | 244 |
| Established patient office or other outpatient visit, 20-29 minutes | 304 | 195 |
| Injection, aflibercept, 1 mg | 190 | 19 |
| New patient complete exam of visual system | 89 | 89 |
| 2d ultrasound scan of eye tissue and structures | 40 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Boston, MA | 68 |
| Ketorolac Tromethamine Other prescribers in Boston, MA | 60 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Boston, MA | 42 |
| Latanoprost Other prescribers in Boston, MA | 27 |
| Dorzolamide Hcl Other prescribers in Boston, MA | 20 |
| Erythromycin (erythromycin base) Other prescribers in Boston, MA | 20 |
| Brimonidine Tartrate Other prescribers in Boston, MA | 12 |
| Bromfenac Sodium | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 13 payments worth $8,539 in total to this clinician.
| Genentech USA, Inc. | $7,853 |
|---|---|
| Alcon Vision LLC | $469 |
| Neurotech Pharmaceuticals, Inc. | $216 |
| Consulting Fee | $6,750 |
|---|---|
| Food and Beverage | $996 |
| Travel and Lodging | $793 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. May 17, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $6,750 |
| Genentech USA, Inc. May 17, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Dallas, TX · in-kind | $458 |
| Genentech USA, Inc. May 17, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Dallas, TX · in-kind | $293 |
| Genentech USA, Inc. May 17, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Dallas, TX · in-kind | $42.61 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $41,942 in research payments for these studies, mostly to the institutions running them.
- A phase 2, multicenter, randomized, double-masked, parallel group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related m…
Kyowa Kirin, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.